文献速递前列腺癌

MRI靶向前列腺穿刺标本的同日荧光共聚焦显微镜检查:可行性研究

Same-day fluorescence confocal microscopy of MRI-targeted prostate biopsies: A feasibility study.
PubMed 文献 · BJU Int · 2026-03-28

单中心前瞻性观察研究纳入44例接受MRI靶向前列腺穿刺的男性,对50条靶向穿刺标本行离体荧光共聚焦显微镜(FCM)检查,以最终组织病理为参考标准。两名泌尿生殖病理医师盲法判读,癌检出总体准确率均为90%,观察者间一致率88%(κ=0.74);每靶点FCM评估可在5分钟内完成。

要点

  • 离体FCM对MRI靶向穿刺标本癌检出准确率达90%,观察者间一致率88%。
  • 标本制备与判读各约2分钟,标准化扫描50秒,每靶点评估<5分钟。
  • 不一致集中于GG2病变和PI-RADS 3靶点,高级别癌与PI-RADS 5病变均一致。

核心结论

  • 离体FCM可在临床可行的时间范围内对MRI靶向前列腺穿刺标本进行快速、准确且可重复的癌检测评估。
  • 研究结果支持FCM作为同日诊断辅助工具,并支持开展评估靶向穿刺期间实时实施的前瞻性试验。

研究设计与样本

  • 单中心前瞻性观察研究,纳入接受MRI靶向经会阴前列腺穿刺的男性。
  • 共分析来自44例患者的50条MRI靶向穿刺标本,其中33条(66%)含前列腺癌,17条(52%)符合临床显著癌(CSC)标准。
  • 靶向穿刺标本经快速吖啶橙浸染后、常规组织病理处理前,使用Histolog® FCM扫描仪行离体成像。
  • 两名委员会认证的泌尿生殖病理医师盲法独立判读FCM图像,将每份标本分类为前列腺癌阳性和阴性以及CSC阳性和阴性,CSC定义为国际泌尿病理学会分级分组(GG)≥2。
  • 以最终组织病理为参考标准计算诊断性能,并测量标本制备、扫描和判读时间以评估工作流程可行性,同时进行观察者间一致性和探索性不一致分析。

主要发现

  • 癌检出方面,Reader 1敏感度87.9%、特异度94.1%,Reader 2敏感度97.0%、特异度76.5%,两名读者总体准确率均为90%。
  • 癌检出的观察者间一致率为88%(κ=0.74),CSC的观察者间一致率为86%(κ=0.61)。
  • 标本制备和判读平均时间各约2分钟,标准化扫描时间为50秒,每靶点完整FCM评估可在5分钟内完成。
  • 不一致集中于GG 2病变和前列腺影像报告和数据系统(PI-RADS)3靶点,而更高级别癌和PI-RADS 5病变均一致。

临床怎么用

  • FCM可作为MRI靶向前列腺穿刺标本的同日诊断辅助工具,在常规组织病理处理前快速提供癌检测信息。
  • 每靶点完整FCM评估可在5分钟内完成,适合在靶向穿刺工作流程中实施。
  • 判读时需注意GG 2病变和PI-RADS 3靶点的不一致风险,高级别癌和PI-RADS 5病变判读一致性较高。

局限性

  • 单中心前瞻性观察研究,样本量有限(44例患者、50条标本)。
  • 研究为离体FCM评估,非靶向穿刺期间实时实施。
  • 不一致分析为探索性,集中于GG 2病变和PI-RADS 3靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the diagnostic performance of ex vivo fluorescence confocal microscopy (FCM) for prostate cancer detection in magnetic resonance imaging (MRI)-targeted biopsy specimens using final histopathology as the reference standard, and to quantify workflow component times relevant to same-day implementation. PATIENTS AND METHODS: In this single-centre prospective observational study, men undergoing MRI-targeted transperineal prostate biopsy were enrolled. Targeted biopsy cores were imaged ex vivo using a Histolog® FCM scanner (SamanTree Medical SA, Lausanne, Switzerland) after rapid acridine orange immersion and prior to routine histopathological processing. Two board-certified genitourinary pathologists independently reviewed FCM images in a blinded fashion and classified each specimen as positive or negative for prostate cancer and clinically significant cancer (CSC), defined as International Society of Urological Pathology Grade Group (GG) ≥2. Diagnostic performance was calculated against final histopathology. Workflow feasibility was assessed by measuring specimen preparation, scanning, and interpretation times. Interobserver agreement and exploratory discordance analyses were performed. RESULTS: A total of 50 MRI-targeted biopsy specimens from 44 patients were analysed, of which 33 (66%) contained prostate cancer and 17 (52%) met criteria for CSC. For cancer detection, Reader 1 achieved 87.9% sensitivity and 94.1% specificity, and Reader 2 achieved 97.0% sensitivity and 76.5% specificity, with overall accuracy of 90% for both readers. Interobserver agreement for cancer detection was 88% (κ = 0.74), and for CSC was 86% (κ = 0.61). Mean specimen preparation and interpretation times were ~2 min each, with standardised scanning time of 50 s, enabling complete FCM assessment in <5 min per target. Discordance was concentrated in GG 2 disease and Prostate Imaging-Reporting and Data System (PI-RADS) 3 targets, while higher-grade cancers and PI-RADS 5 lesions were uniformly concordant. CONCLUSION: Ex vivo FCM provides rapid, accurate, and reproducible assessment of MRI-targeted prostate biopsy specimens for cancer detection within clinically feasible timeframes. These findings support FCM as a same-day diagnostic adjunct and justify prospective trials evaluating real-time implementation during targeted biopsy.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Younis SK, Watfa M, Wang L, et al. Same-day fluorescence confocal microscopy of MRI-targeted prostate biopsies: A feasibility study. BJU Int. 2026. PMID: 41902616. doi:10.1111/bju.70263

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。